



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Public Summary

Summary for ARTG Entry:	100128	Xue Fu Zhu Yu Tang a.k.a. Persica & Cnidium Blood Moving Formula
ARTG entry for	Medicine Listed	
Sponsor	Sun Herbal Pty Ltd	
Postal Address	Unit 5/25 Garema Cct, Kingsgrove, NSW, 2208 Australia	
ARTG Start Date	10/03/2004	
Product Category	Medicine	
Status	Active	
Approval Area	Listed Medicines	

Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

This medicine contains a preparation of Carthamus tinctorius flower for oral use. From 1 July 2011 all Listed Medicines containing preparations of Carthamus tinctorius flower for oral use must include the label advisory statement 'Do not use if pregnant or likely to become pregnant'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

Products

1 . Xue Fu Zhu Yu Tang a.k.a. Persica & Cnidium Blood Moving Formula

Product Type	Single Medicine Product	Effective Date	1/06/2018
--------------	-------------------------	----------------	-----------

Permitted Indications

Traditionally used in Chinese medicine to invigorate/activate Blood

Traditionally used in Chinese medicine to eliminate/reduce/remove/resolve/dissipate blood-stasis

Traditionally used in Chinese medicine to increase/augment/generate/promote/strengthen qi

Indication Requirements

If TCM terminology is used on medicine label, label statement: Talk to a TCM practitioner/health professional if you are unsure if this medicine is right for you.

Product presentation must not imply or refer to serious cardiovascular conditions.

Standard Indications

No Standard Indications included on Record

Specific Indications

No Specific Indications included on Record

Warnings

Do not use if pregnant or likely to become pregnant (or words to that effect)

If symptoms persist consult your healthcare practitioner (or words to that effect).

Additional Product information



Australian Government
Department of Health and Aged Care
Therapeutic Goods Administration

Pack Size/Poison information

Pack Size

Poison Schedule

Components

1 . Formulation 1

Dosage Form Capsule, hard

Route of Administration Oral

Visual Identification

Active Ingredients

Achyranthes bidentata root Extract dry concentrate	28.8 mg
Equivalent: Achyranthes bidentata (Dry)	172.8 mg
Angelica polymorpha root Extract dry concentrate	21.6 mg
Equivalent: Angelica polymorpha (Dry)	129.6 mg
Bupleurum falcatum root Extract dry concentrate	21.6 mg
Equivalent: Bupleurum falcatum (Dry)	129.6 mg
Carthamus tinctorius flower Extract dry concentrate	21.6 mg
Equivalent: Carthamus tinctorius (Dry)	129.6 mg
Citrus aurantium fruit Extract dry concentrate	21.6 mg
Equivalent: Citrus aurantium (Dry)	129.6 mg
Glycyrrhiza uralensis root Extract dry concentrate	12 mg
Equivalent: Glycyrrhiza uralensis (Dry)	72 mg
Ligusticum striatum root Extract dry concentrate	21.6 mg
Equivalent: Ligusticum striatum (Dry)	129.6 mg
Paeonia lactiflora root Extract dry concentrate	21.6 mg
Equivalent: Paeonia lactiflora (Dry)	129.6 mg
Paeonia obovata root Extract dry concentrate	21.6 mg
Equivalent: Paeonia obovata (Dry)	129.6 mg
Platycodon grandiflorus root Extract dry concentrate	14.4 mg
Equivalent: Platycodon grandiflorus (Dry)	86.4 mg
Prunus persica seed Extract dry concentrate	21.6 mg
Equivalent: Prunus persica (Dry)	129.6 mg
Rehmannia glutinosa root Extract dry concentrate	36 mg
Equivalent: Rehmannia glutinosa (Dry)	216 mg
Salvia miltiorrhiza root Extract dry concentrate	36 mg
Equivalent: Salvia miltiorrhiza (Dry)	216 mg

Other Ingredients (Excipients)

hydrolysed gelatin

titanium dioxide

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary